Galleri is a blood test that aims to detect over 50 types of cancer early. It analyzes cell-free DNA (cfDNA) and methylation patterns to identify potential cancer signals. The test is intended for ...

Fred Hutch Cancer Center is leading the newly launched Vanguard Study, a national study of a new type of blood test that screens for several different cancers called multi-cancer detection (MCD) tests ...

PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (GH), a leading precision oncology company, today announced that its Shield multi-cancer detection (MCD) test has been granted Breakthrough ...

The tests have not been approved by federal regulators, but that hasn’t stopped patients from wanting them — and doctors from worrying.

Comprehensive Cancer Detection: SeekInCare leverages shallow whole-genome sequencing of cell-free DNA (cfDNA) and measures seven protein tumor markers from 8ml peripheral blood. The test analyzes ...

(RTTNews) - Exact Sciences Corp. (EXAS) announced the U.S. launch of Cancerguard™, its multi-cancer early detection or MCED blood test, now available as a laboratory-developed test or LDT. Cancerguard ...

Using a single blood sample, multi-cancer early detection (MCED) tests screen for numerous types of cancers, including breast, ovarian, colorectal, pancreatic and prostate cancers. Trials are underway ...